Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GKB OphthalmicsNSE:GKB 44 3-Year EBITDA Growth Rate is 24.20% as of Jun. 2026. GuruFocus rates NSE:GKB with a GF Score™ of 44/100 and a GF Value™ of ₹126.23 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 690 Medical Devices & Instruments companies, GKB Ophthalmics ranks better than 70.58% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 24.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of GKB Ophthalmics was 61.10% per year. The lowest was -39.30% per year. And the median was -2.40% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
GKB Ophthalmics 3-Year EBITDA Growth Rate Related Terms
NSE:GKB vs ISRG, BDX, MDLN: 3-Year EBITDA Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, GKB Ophthalmics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GKB Ophthalmics 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, GKB Ophthalmics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where GKB Ophthalmics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 24.20% mean?
GKB Ophthalmics (NSE:GKB) has a 3-Year EBITDA Growth Rate of 24.20% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for GKB Ophthalmics and its competitors. According to the industry distribution chart, GKB Ophthalmics ranks #203 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 29.4%.
Is GKB Ophthalmics' 3-Year EBITDA Growth Rate too high?
GKB Ophthalmics' current 3-Year EBITDA Growth Rate is 24.20%. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.20. GKB Ophthalmics' value of 24.20% is 195.1% above this industry median. Based on the distribution chart, GKB Ophthalmics ranks #203 out of 690 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, GKB Ophthalmics has a GF Score™ of 44/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GKB Ophthalmics' 3-Year EBITDA Growth Rate compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, GKB Ophthalmics ranks #203 out of 690 companies for 3-Year EBITDA Growth Rate. This puts GKB Ophthalmics in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.20. GKB Ophthalmics' value of 24.20% is 195.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GKB Ophthalmics's current 3-Year EBITDA Growth Rate of 24.20% is 195.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for GKB Ophthalmics and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GKB Ophthalmics's current 3-Year EBITDA Growth Rate is 24.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GKB Ophthalmics stock overvalued right now?
Based on GuruFocus' analysis, GKB Ophthalmics (NSE:GKB) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹126.23, compared to a current price of ₹63.00 — trading 50.1% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 24.20% and 195.1% above the Medical Devices & Instruments industry median of 8.20. GKB Ophthalmics' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For GKB Ophthalmics (NSE:GKB), the current 3-Year EBITDA Growth Rate is 24.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GKB Ophthalmics (NSE:GKB) Overvalued in 2026?
Based on GuruFocus' analysis, GKB Ophthalmics stock appears to be undervalued.
The current stock price of ₹63.00 is trading 50.1% below its estimated GF Value™ of ₹126.23.
GuruFocus considers GKB Ophthalmics to be Significantly Undervalued.
Key valuation signals for NSE:GKB:
3-Year EBITDA Growth Rate: 24.20%
GF Value™: ₹126.23 vs. price of ₹63.00 (50.1% below fair value)
Industry Position: 195.1% above the Medical Devices & Instruments median (#203 of 690)
No single metric tells the full story. See the NSE:GKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GKB Ophthalmics Ltd is an India-based company engaged in manufacturing and exporting ophthalmics lenses. It manufactures glass and plastic lenses both semi-finished and finished forms. The other products of the company include Organic lenses, Glass moulds, and Bifocal moulds. The company sells its products in India and also exports globally. Geographically, the majority of its revenue is generated from outside of India.
44GF Score
Get the complete analysis for NSE:GKB
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GKB has been successfully added to your 
